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Abstract
The prevalence of diabetes com-
plications is a significant public
health problem with a consider-
able economic cost. Thus, the
timely diagnosis of complications
and prevention of their develop-
ment will contribute to increasing
the length and quality of patient
life, and reducing the economic
costs of their treatment. This arti-
cle aims to review the current
state-of-the-art biophotonics technologies used to identify the complications of
diabetes mellitus and assess the quality of their treatment. Additionally, these
technologies assess the structural and functional properties of biological tis-
sues, and they include capillaroscopy, laser Doppler flowmetry and hyper-
spectral imaging, laser speckle contrast imaging, diffuse reflectance
spectroscopy and imaging, fluorescence spectroscopy and imaging, optical
coherence tomography, optoacoustic imaging and confocal microscopy. Recent
advances in the field of optical noninvasive diagnosis suggest a wider introduc-
tion of biophotonics technologies into clinical practice and, in particular, in
diabetes care units.
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1 | INTRODUCTION
Studies related to diabetes mellitus (DM) are attracting
increased attention from scientists around the world. DM
is a group of chronic long-term diseases characterized by
various metabolic disorders. There are two main forms of
diabetes: type 1 and type 2 diabetes, however, diabetes
can also occur during pregnancy and under the influence
of other conditions. The clinical course of diabetes is
characterized by a state of hyperglycemia resulting from
insulin deficiency or insulin resistance. Chronic hyper-
glycemia leads to blood vessels damage, which causes the
development of diabetes complications [1, 2].
Over the past few years, the prevalence of diabetes has
reached alarmingly high levels. The number of diagnosed
patients with this disease already amounts to approxi-
mately half a billion worldwide, and this number will only
grow in the near future, according to forecasts [3].
Owing to the increasing prevalence of the disease,
complications of diabetes is now considered one of the
most important problems of modern healthcare.
According to experts, almost every patient with diabetes
will develop at least one or more complications through-
out his or her life [2, 4]. Complications of diabetes range
from acute, life-threatening conditions, such as severe
hypoglycemia or ketoacidosis, to chronic, debilitating
complications affecting many organs and organ systems,
such as retinopathy, nephropathy, neuropathy and car-
diovascular disease. Chronic complications of diabetes
are formed under the influence of prolonged exposure to
high levels of glucose in the body [2]. They are associated
with disorders of the cardiovascular and nervous systems.
Ultimately, these complications can lead to severe vision
loss and blindness, end-stage of renal disease and need
for hemodialysis or transplantation, development and
infection of diabetic ulcers, amputations, heart failure,
stroke and so on. Currently, it has been demonstrated
that the length and health-related quality of life of dia-
betic patients are determined by the presence and sever-
ity of chronic complications of this disease, as well as the
quality of their treatment [5, 6]. In this regard, there is an
urgent need for the early detection and prevention of the
development of diabetic complications.
Biophotonics methods represent a viable solution to
this problem. Various spectroscopy and imaging technol-
ogies can provide information on the optical properties of
skin, which are directly related to its blood supply, degree
of oxygenation and the presence of chromophores [7].
Table 1 presents the various methods of biophotonics and
their application in studies of DM complications.
Thus, biophotonics present unique possibilities for both
structural and functional analysis of biological tissues, as
well as early and noninvasive diagnosis and monitoring of
the effectiveness of the therapy in various diseases.
Recently, there has been a surge of interest in the use of
optical technologies in diabetes. Several reviews have been
published in this area, including articles examining the
change in the optical properties of biological tissues related
to DM [67], a review of technologies for imaging ulcers
[68], and technologies for studying microcirculation in DM
[23]. To the best of our knowledge, there are no review
articles that focuses on biophotonics methods for investi-
gating all the DM complications, including retinopathy,
neuropathy, microangiopathy and diabetic ulcers.
This article aims to combine the accumulated experi-
ence in the field of optical noninvasive diagnosis of diabe-
tes complications and provide a comprehensive review of
the literature in this area.
TABLE 1 Body parameters evaluated by biophotonics in the
diagnosis of diabetes complications
Biophotonics method Characteristics assessed
Capillaroscopy Vascular bed morphology
[8–10] and blood flow
velocity [11]
Laser Doppler flowmetry
and imaging
Blood flow [12–16] and blood
flow oscillations [17–20]
Laser speckle contrast
imaging
Blood flow, diabetic wounds
[21–24]
Diffuse reflectance and
near-infrared spectroscopy
and imaging
Tissue oxygen saturation,
chromophores content, blood
volume and diabetic wounds
[25–32]
Hyperspectral imaging Chromophores content, the
thickness of the epidermis,
blood filling, oxygen
saturation, wound
development prediction and
healing assessment [24, 33–36]
Fluorescence spectroscopy
and imaging
Accumulation of AGE [37, 38],
metabolic activity of tissue
[39, 40] and diabetic wounds
[41]
Optical coherence
tomography
Retinal morphology [42–47]
retinal nerves condition [48,
49],
retinal perfusion measurement
[50–53], protein glycation
[54–57]
Confocal microscopy Corneal morphology, corneal
nerves condition [58–62]
Raman spectroscopy Collagen degradation,
accumulation of AGE [63]
and protein glycation [64, 65]
Terahertz spectroscopy Water content [66]
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In this review, the following optical technologies for
studying DM complications will be considered: cap-
illaroscopy, dynamic light scattering methods (laser
Doppler flowmetry [LDF] and imaging, laser speckle-
contrast imaging [LSCI]), diffuse reflectance spectroscopy
(DRS) and imaging, fluorescence spectroscopy and imag-
ing, optical coherence tomography and confocal micros-
copy. We specifically focused on methods for noninvasive
diagnosis and monitoring of diabetes complications, not
including optical studies of blood glucose levels.
2 | OPTICAL APPROACHES IN
DIAGNOSTICS
2.1 | Capillaroscopy
Capillaroscopy is a convenient method to assess the mor-
phology of the vascular bed and its changes in vivo as the
disease develops. To conduct the capillaroscopic studies,
a microscope with a lower or higher magnification is usu-
ally used, to obtain panoramic images of the capillary bed
or enlarged images of individual capillaries and their
groups, respectively. The studies are mainly carried out in
the nail bed since the capillary arc extends parallel to the
skin surface. Therefore, it is possible to monitor the blood
flow in the capillaries at a sufficiently large increase,
while in other parts of the skin the capillaries are perpen-
dicular to the skin surface. During the study, the hand is
usually placed on the examination table at heart level
and a drop of immersion oil is deposited on the nail bed,
to increase the transparency of the skin [69]. The inner
surface of the lower lip is also commonly researched for
capillaroscopy [70], although the research there is associ-
ated with more significant methodological difficulties.
Capillaroscopy has been used to study the state of
microcirculation since the 19th century. Historically, this
technique is the most widespread in the studies of vascu-
lar disorders in rheumatic diseases [69], although the
spectrum of application of this technology is quite exten-
sive. Furthermore, capillaroscopy can be used to estimate
the number of visualized capillaries in the nail bed, den-
sity of the capillary network, presence of tortuous capil-
laries and hemorrhages and diameters of the arterial and
venous parts of the capillary [71]. These are important
diagnostic parameters of the condition of the cardiovas-
cular system. To evaluate these parameters, static images
of the capillary network are usually recorded with subse-
quent analysis of the photographs.
Modern video capillaroscopy systems have high-speed
cameras and side lighting with an average of 2 to 4 high-
brightness LEDs with a wavelength of 520 to 530 nm,
which provides maximum contrast of the images of the
capillary network due to the absorption of light by blood
in this wavelength range.
Diabetes is one of many diseases leading to abnormal-
ities in the morphology and physiology of the capillary
bed. Numerous studies have shown that patients with
diabetes demonstrate microvascular changes, which were
recorded by the capillaroscopy method. Among such
changes, tortuosity, dilated capillaries and a decrease in
the capillary network density are distinguishing features
[8, 72–76]. Figure 1 presents the altered structure of the
capillary bed of a patient with DM obtained by
capillaroscopy.
In the studies of children and adolescents with diabe-
tes avascular zones and hemorrhages were found [77]. In
addition, it was shown that the presence and severity of
microvascular changes largely depends on the presence
of DM complications, duration of the disease and quality
of metabolic control [78, 79]. Attempts have also been
made to evaluate the difference in capillaroscopic pic-
tures of patients with type 1 and type 2 diabetes; how-
ever, the results of these studies are contradictory [9, 78].
A promising area of research is the dynamic assess-
ment of the velocity of blood flow throughout the vessels
in control and diabetic subjects, as well as the assessment
of changes in this parameter when exposed to external
factors (e.g., temperature and occlusion). Some studies
have already shown that blood flow velocity is signifi-
cantly reduced in patients with diabetes compared with
healthy controls, especially in those with complications
[8, 11]. Moreover, the value of the peak blood flow veloc-
ity during reactive postocclusive hyperemia is reduced in
patients with diabetes [8]. Recent advances in signal
processing for high-speed video capillaroscopy have
shown the possibility of evaluating blood flow fluctua-
tions in individual capillaries associated with physiologi-
cal regulation of blood flow [80] (a more detailed
description of blood flow fluctuations is presented in the
following section). Research in this area is promising for
the diagnosis of diabetes complications.
2.2 | Dynamic light scattering
The basic principles of dynamic light scattering (DLS) are
based on phenomena such as frequency shift and inten-
sity fluctuations of light propagated through a turbid tis-
sue-like scattering medium containing moving particles.
This method is typically based on the illumination of bio-
logical tissues by continuous laser radiation and simulta-
neously recording the fluctuations of the intensity of the
scattered light utilizing a single-mode optical fiber or
camera [81]. The blood flow velocity is calculated
according to the field autocorrelation function.
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DLS methods have been used to measure the velocity
of moving particles since the 1960s [82]. Several methods
for measuring the velocity of both flowing and diffusing
particles for single scattering cases have been developed
[83–85], and a DLS theory was developed for a multiply
scattering medium [86–88]. Among the DLS-based
methods, LDF and LSCI are extensively used for monitor-
ing the blood flow in skin for various physiological and
pathological conditions [89–94]. In DLS techniques, red
(630-650 nm) and near-infrared (750-1100 nm) wave-
lengths of the laser source are usually used (most com-
monly used semiconductor lasers).
2.2.1 | Laser Doppler flowmetry
Currently, LDF is a widely used method for the in vivo
assessment of the state of microcirculatory blood flow.
Laser Doppler measures the total local microcirculatory
blood perfusion. This technique is based on tissue sensing
by laser light and analysis of the light scattered by the tis-
sue. Light impinging on moving red blood cells
undergoes a Doppler shift in frequency while light hitting
static objects remains unchanged.
Numerous studies have been conducted using LDF to
assess peripheral arterial disease (PAD) in diabetes; both
monitoring and imaging technologies were used to evalu-
ate the dynamics of blood flow at an individual point and
over a larger area, respectively. The results of the studies
on peripheral blood flow under basal conditions are con-
troversial. Some studies agree that there are no statisti-
cally significant differences in the perfusion parameters
between the groups of patients with diabetes and healthy
controls, although the LDF signal in patients is lower in
absolute values [95–97]. In contrast, other studies note
significantly higher values of the microcirculation index
in diabetics [12, 98, 99]. Among the latter, the results are
usually associated with the effect of long-term sympa-
thetic neuropathy on the microcirculatory function,
which causes an increase in cutaneous blood flow, espe-
cially in the lower extremities [100, 101].
When conducting measurements using the LDF
method, important diagnostic information about the reg-
ulation of the microvasculature by various body systems,
including nervous and humoral regulation, can also be
obtained. The recorded signal can be decomposed into its
constituent oscillatory components using wavelet analy-
sis. Previous studies have noted the following oscillatory
components and their physiological causes [102, 103]:
frequency intervals of 0.005 to 0.0095 Hz and 0.0095 to
0.021 Hz correspond to the regulation of blood flow by
endothelium cells through the release of nitric oxide and
other vasoactive substances into the vessel lumen, respec-
tively; range 0.021 to 0.052 Hz is associated with the
influence of microvascular innervation; fluctuations with
a frequency of 0.052 to 0.145 Hz correspond to the influ-
ence of vascular-smooth-muscle activities; 0.45 to 1.6 Hz
and 0.2 to 0.45 Hz frequency bands carry information
about the influence of heart rate and thorax movement
on the peripheral blood flow, respectively.
One of the main drawbacks imposed on the LDF
technique is the lack of absolute perfusion units and the
high heterogeneity of the signal between the subjects and
within the same subject when measured from different
points of the body. Nonetheless, LDF can have excellent
temporal resolution. In this regard, the method has found
wide applications in the analysis of the microcirculatory
bed reaction to various physiological and pharmacologi-
cal stimuli. Occlusion, orthostatic, iontophoretic and
local heating tests are used to assess microcirculatory dis-
orders in diabetes. Acetylcholine (Ach) and sodium
nitroprusside are usually used as pharmacological stim-
uli. In a study on the microcirculatory system reactivity
using pharmacological tests, a significant decrease in the
maximum vasodilation in DM patients compared with
the controls was observed [104].
Of the physiological effects, local thermal exposure or
local heating test is most often used. The popularity of
FIGURE 1 Capillaroscopy of a
diabetic patient: altered vascular
structure characterized by tortuous,
cross-linked, and dilated capillaries, A,
as well as ramification and a slight
decrease in capillary density, B
[10]. Reproduced with permission of
Elsevier
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this test could be explained by the fact that it is painless,
easy to use and noninvasive. Local heating allows evalua-
tion of two vasodilation mechanisms: the reflex reaction
of the local sensory nerves and endothelium-dependent
vasodilation, which occurs during prolonged heating
[105]. A recent review and meta-analysis of articles study-
ing the use of LDF in conjunction with a local heating
test for assessing microcirculation in diabetes [16]
showed that most studies indicated reduced vasodilation
in patients with diabetes in response to local heating. In
addition, this parameter was even more reduced in a
group of patients with diagnosed diabetes complications
(such as diabetic dermopathy, neuropathy or angiopathy)
compared to patients without complications [41,
106]. However, it should be noted that these studies are
significantly limited by the fact that the conditions for a
local heating test, in particular, are not standardized, and
different authors apply different experimental conditions.
The studies used different heating modes with different
maximum temperatures. Additionally, the rate of tissue
heating was not indicated in some of the studies, and dif-
ferent durations of the heating stage were used in differ-
ent protocols. In general, a significantly reduced level of
the LDF signal can be noted in patients with diabetes
under maximum vasodilation caused by heating [12,
13, 16, 20, 107, 108].
The assessment of reactive postocclusion hyperemia
(PORH) in arterial occlusion is also a widely used test to
assess the state of microcirculatory blood flow in various
pathological conditions, including diabetes. A positive
correlation between the time to peak during PORH and
the presence of active or past foot ulcers was found in
subjects with diabetes by means of LDF [109]. Moreover,
it has been observed that the restoration of the initial
blood flow after PORH is slower in subjects with diabe-
tes [104].
Although the analysis of blood flow fluctuations regis-
tered by the LDF in patients with diabetes is of consider-
able scientific interest, relatively few studies have been
undertaken in this area. Patients with diabetes were
found to have impaired vasomotion with a frequency of
0.1 Hz [17], which corresponds to the effect of sympa-
thetic activity. It has been suggested that such abnormali-
ties in blood flow regulation might be symptoms of early
sympathetic dysfunction and could precede sympathetic
neuropathy [18, 110].
In our studies, we also demonstrated differences in
the LDF signals between healthy subjects and patients
with diabetes under normal temperature conditions and
local heating [19, 20]. It was found that patients with DM
have a lower vasodilation rates and a less pronounced
response in the frequency range close to 0.14 Hz, which
is consistent with previous studies by other authors [111].
Some studies indicate a tendency toward a decrease
in vascular function in relatives of patients and volun-
teers with impaired glucose tolerance [95]. A recent study
conducted with LDF confirmed a gradual change in
parameters from the control group to the prediabetic and
diabetic group [112]. The deterioration of microvascular
function was also found in individuals with metabolic
syndrome [113].
In addition to the limitations indicated above in the
studies of microcirculation by the LDF method, poor
standardization of LDF equipment can contribute to cir-
cumstances that prevent its wider use in the clinic, which
greatly complicates the comparison of the results
obtained by different authors.
2.2.2 | Laser Doppler perfusion imaging
As mentioned above, one of the distinguishing features of
skin microcirculation is its huge heterogeneity. Single-point
measurements of LDF can have significant differences
when carried out even at a short distance. To overcome this
problem, laser Doppler perfusion imaging (LDPI) technol-
ogy was developed. The first implementation of this tech-
nology used a moving mirror that changed the direction of
the laser and scanned the tissue point by point, so that the
blood flow map could be restored [114, 115]. At present,
full-field LDPI systems are proposed and are the objects of
active research. The method has found wide application in
the assessment of wound healing, including wounds arising
from diabetes.
In addition to wound studies, LDPI together with var-
ious functional influences was used to evaluate other dis-
orders in diabetes. Using LDPI and local temperature
effects, impaired nervous function was shown in patients
with diabetes [14]. The method was also used to study
the effect of metformin administration on changes in
microvascular function in a nondiabetic population
[15]. The study included evaluation of microvascular
function with vasoactive substances and iontophoresis,
and it was aimed at determining the effectiveness of met-
formin in improving the endothelial function in
nondiabetic subjects. At the end of the study, the metfor-
min-treated subjects showed a clear improvement in ACh
response.
2.2.3 | Laser speckle contrast imaging
Laser speckle contrast imaging (LSCI) is another power-
ful dynamic light scattering technique allowing non-
contact full-field real-time visualization of flows. LSCI for
biomedical applications is now gaining increasing
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attention. In LSCI information about blood flow is
obtained by analyzing the speckle contrast variations
[116]. Light scattered on the sample falls on the camera,
where speckles are recorded. Speckles are formed by
interference between photons reaching the same pixel
after passing through different paths. The contrast ratio is
related to the speed of moving particles causing blurring
of the spot, which characterizes the blood flow intensity
in biological tissues.
Although this technology has been used to assess
the state of blood flow in various areas of medicine,
currently, it is rarely used to study microcirculation in
diabetes. It was previously shown that LSCI has excel-
lent spatial and temporal resolution, as well as repro-
ducible measurement results [117]. Most studies using
LSCI were aimed at studying the state of cerebral
[118, 119] and retinal blood flow [120–122]. These
sites are most convenient for research as closely lying
vessels provide a higher signal-to-noise ratio. Later,
this technology was applied in surgical interventions
[123, 124].
Recently, LSCI was used in the study of endothelial
function in patients with type 1 diabetes [22]. The study
used acetylcholine and occlusion tests, and it was found
that, in patients, endothelium-dependent vasodilation
was significantly reduced in response to both stimuli.
LSCI was successfully applied in the studies of wound
healing both in animal models [125, 126] and patients
with DM [21]. Figure 2 presents a color photograph of a
foot with diabetic ulcers and the corresponding LSCI
image.
However, LSCI technique, like other DLS methods, is
still suffering from some critical drawbacks. The major
one is the significant temporal and spatial variability of
the measurements. The temporal variability is usually
related to the intrinsic nonstationarity of microcirculation
and associated complex dynamics within biological tissue
itself, which is also known as, so-called “biological zero”
[127]. Although methods for analyzing the dynamics of
the LSCI signal were presented [128], there is the absence
of a standardized quantitative relationship with the real
physiological parameters of blood flow, expressed in the SI
units. Whereas, currently available LSCI devices are able
to observe only the relative blood changes with no quanti-
tative scale of measure, resulting in usage of the arbitrary
units. Another major drawback is associated with the
approximate account of the detected light scattered with
biological tissues, especially in respect to the finite obser-
vation time in the statistical sense, known as ergodicity
[129–131].
2.3 | Diffuse reflectance spectroscopy
DRS has widespread application in medicine. Many stud-
ies have used the method to separate malignant and nor-
mal tissues in various areas of oncology [132, 133]. An
analysis of the changes in the diffuse reflection of tissues
can provide information about their morphological and
physiological state.
DRS techniques have been implemented to assess
the peripheral blood flow and oxygenation saturation
state. The method is able to provide continuous nonin-
vasive measurement of changes in the oxygenated
(cHbO2) and deoxygenated (cHb) hemoglobin concen-
tration. The studies have shown that some parameters
obtained by DRS significantly correlate with measure-
ments of the ankle-brachial index [134], which is a com-
monly used parameter for assessing the risk of
developing diabetes complications [135].
The DRS method has been used in the diagnosis of
diabetes-related blood flow disorders for over 15 years.
A decrease in the level of blood flow in patients with
type 1 diabetes compared with healthy control was
shown in the basal state and during exercise
[25]. Impaired blood flow while exercising was also
shown in type 2 diabetic patients regardless of the pres-
ence or absence of peripheral arterial occlusive disease
[26]. Significant decrease in the total hemoglobin con-
centration was observed by DRS in diabetic subjects
compared to a control group [28].
The method also found use in the evaluation of foot
ulceration and wound healing processes. Usually, when
diagnosing the state of oxygenation by this method, an
FIGURE 2 Laser speckle-contrast imaging image of a diabetic
foot with an active ulcer in the process of healing [24]. Reproduced
with permission of Springer Nature
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estimate of the area under the curve of the diffuse reflec-
tance spectrum is used [136]. Some authors propose a
ratio of the diffuse reflectance at different wavelengths
as a diagnostic parameter. Usually, isobestic points of
oxy- and deoxyhemoglobin are selected for these pur-
poses [27]. By applying this approach, changes in the
level of tissue oxygenation were studied to differentiate
patients with different severities of complications [29]
and to predict the healing process of diabetic ulcers [27].
Near-infrared spectroscopy (NIRS) is also a wide-
spread technology for accessing cutaneous oxygen con-
centration. It was proposed in 1977 [137] and was widely
used to estimate blood circulation in the brain and other
organs [138–140] in normal and pathological conditions.
NIRS utilizes red or near-infrared light to probe the tissue
and analyzes the absorption of light on the specific wave-
lengths, providing information on the total hemoglobin,
oxyhemoglobin, deoxyhemoglobin concentrations and
tissue oxygen saturation.
NIRS is widely used in the diagnosis and evaluation of
the diabetic foot ulcers treatment. Previous studies have
shown that NIRS has the potential to predict the diabetic
ulcers outcome [30]. The ability of NIRS to differentiate
healing and nonhealing ulcers based on the degree of
absorption of near-infrared light [31], which is associated
with the concentration of hemoglobin, was shown.
In recent studies related to diabetes, NIRS was further
developed. Noninvasive wearable wireless devices that
implement this technology are being developed to visual-
ize the condition of ulcers at home [32].
2.4 | Hyperspectral imaging
Hyperspectral imaging (HSI) is a modern implementa-
tion of the DRS method providing information about
the tissue oxygenation state. It is able to detect sys-
temic and local microcirculatory changes associated
with DM [141]. The technology is most commonly used
to analyze the development of wounds, including dia-
betic ulcers and the results of burns [68]. To implement
hyperspectral measurements, a series of images of the
object under the study is registered in narrow fre-
quency ranges, forming a hypercube. The hypercube
has two spatial coordinates (x, y) and one spectral (λ).
The analysis of the data contained in the hypercube
allows one to assess the content of chromophores in
the biological tissue studied, thickness of the epider-
mis, blood filling and oxygen saturation. Figure 3
shows visible and hyperspectral images of a foot taken
with the use of HSI.
The studies conducted using this technology have
shown the ability of the method to evaluate the effective-
ness of the diabetic ulcer treatment, and predict their
development even before they appear. The study carried
out by Yudovski et al. showed that by using HSI, it was
possible to register the changes in the epithelium thickness
that precede the formation of an ulcer [142]. The visible
images and oxygen saturation maps from a patient with a
developing diabetic foot ulcer are shown in Figure 4.
The study conducted by Khaodhiar et al. investigated
the diabetic wound healing process over 6 months using
hyperspectral medical technology [33].
The study was conducted on patients with type 1 diabe-
tes and registered values corresponding to concentrations
of oxy- and deoxyhemoglobin with subsequent calculation
of the healing index. It was shown that HSI successfully
distinguishes between healing ulcers and ones that failed
to heal. Another study aimed at studying the healing of
diabetic ulcers through HSI included patients with type
1 and type 2 diabetes [34]. The tissue oxygenation maps
were constructed from oxy- and deoxyhemoglobin values
determined for each pixel in the image. Linear discrimi-
nant analysis was used to calculate the healing index, by
separating healed and unhealed ulcers. It was concluded
that the technique could accurately predict wound healing
in advance, providing information necessary for treatment
and monitoring of diabetes complications.
FIGURE 3 A, Visible and B,
hyperspectral images of a diabetic foot
ulcer taken with the hyperspectral
imaging system [24]. Reproduced with
permission of Springer Nature
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In summary, HSI can accurately predict ulcer healing
in a few months and identify ulcers that are at risk of not
healing, and therefore, could be used to screen for lower-
extremity complications due to diabetes. Emerging tech-
nologies for the collection and analysis of hyperspectral
data [143], including artificial intelligence systems, sug-
gest an even wider introduction of this technology in
clinical diagnostics.
2.5 | Fluorescence spectroscopy and
imaging
The accumulation of advanced glycation end-products
(AGEs) and oxidative stress are among the key mecha-
nisms for the development of diabetes complications
[144, 145]. The AGEs are proteins and lipids that become
glycated as a result of exposure to sugars and known as
FIGURE 4 Visible images, A-D, and
corresponding oxygen saturation maps, E-H, of the
foot of diabetic subject with developed ulcer
[36]. Reproduced with permission of John Wiley
and Sons
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glycotoxins due to their harmful effect. By accumulating
in the body, AGEs start the process of protein cross-
linking, in particular, in collagen, myelin and hemoglo-
bin molecules. The glycated proteins fluoresce when irra-
diated with UV light. Figure 5 shows the fluorescence of
AGE in the arm by multiphoton fluorescence spectros-
copy. In the 1990s, the fluorescence of cross-linked pro-
teins was shown to increase significantly with aging and
in patients with diabetes [146]. In the early stages, the
AGE fluorescence studies were performed in blood and
urine samples and skin biopsies. The cross-linked protein
fluorescence has been shown to be higher in patients
with complications of diabetes, particularly kidney dis-
ease, compared to those without complications [147].
Meerwaldt et al. reported one of the first studies of
noninvasive AGE-accumulation measurement using fluo-
rescence spectroscopy [37]. They validated skin
autofluorescence measurements against the results of
biochemical analyses of skin biopsies in healthy subjects
and patients with DM but with no clinical signs of com-
plications (see Figure 6). In the skin of patients with DM,
the AGE autofluorescence significantly correlates with
the long-term level of glycated hemoglobin (HbA1c) and
not with its current level [149, 150]. Thus, the level of tis-
sue AGEs reflects long-term metabolic disorders in diabe-
tes and can be considered an indicator of “glycemic
memory.” For this reason, many studies have indicated
that the level of AGE fluorescence can be an independent
predicator of microvascular complications, neuropathy
and renal disease.
Gerrits et al. studied 881 patients with type 2 diabetes
to determine the feasibility of skin fluorescence
assessment as a marker for the development of diabetic
complications [38]. The study lasted 5 years during which
patients underwent measurement at least once a year.
They found that skin autofluorescence was significantly
associated with the development of neuropathy and
(micro)albuminuria, but not with diabetic retinopathy
(DR). In a further multi-center study, it was confirmed
that skin autofluorescence is associated with the risk of
micro- and macrovascular complications [151]. A study
by Yasuda et al. evaluated the change in skin fluores-
cence in patients with DR [152]. They showed a gradual
increase in this parameter during the development of ret-
inopathy (from patients without complications to patients
with nonproliferative and proliferative forms of retinopa-
thy). Several studies have also shown an increase in the
lifetime of AGE-associated fluorescence in the eyes, skin
FIGURE 5 Example of a grayscale AGE-index image of the
volar side of the arm detected by a multiphoton fluorescence
imager [148]. The colored region indicate the region of interest
selected for the AGE-index calculation. Reproduced with
permission of Elsevier
FIGURE 6 A, Collagen-linked and, B, pentosidine
fluorescence [37]. Reproduced with permission of Springer Nature
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and dentin of patients with diabetes [153–155]. In the
studies, the authors use two- and three-term exponential
fitting with the estimation of the parameters related to
the time constant of fluorescence relaxation as well as
the intensity of the corresponding fluorescent compo-
nents. The gradual decrease in the average lifetime
parameters of the first and second decay components
with the increase of the AGEs has been demonstrated by
the incubation of the collagen gel and dentin in ribose
[39]. Remarkably, no significant differences in lifetime
parameters were found in measurements on skin of dia-
betic patients and healthy volunteers [153], whereas an
increase in cutaneous fluorescence is indicative of the
development of diabetic ulcers [108, 156].
A substantial number of studies examined the appli-
cability of AGE fluorescence in evaluating the risk of all-
cause mortality and cardiovascular morbidity and mortal-
ity [157–159]. A recent review and meta-analysis indi-
cated that elevated levels of AGE fluorescence could be a
predictor of cardiovascular and all-cause mortality in
patients with diabetes related cardiovascular and renal
diseases [159]. This parameter was also demonstrated to
effectively assess the 5-year risk of amputation in patients
with PAD [160]. The widespread use of the AGE-level
assessment in the diagnosis of DM complications and
other diseases ultimately led to the successful commer-
cialization of devices based on this technology. The first
commercially available device was released by the Dutch
company DiagnOptics, called the AGE-Reader. A photo-
graph of the device is shown in Figure 7.
Although previous studies have shown a significant
correlation of the skin autofluorescence level with the
amount of collagen and AGEs [37, 162, 163], other
fluorophores also contribute to the overall signal. The
important components are the redox regulated
fluorophores, NADH and FAD, which also exhibit
autofluorescence. The redox status of tissues can be deter-
mined by assessing the fluorescence ratio of these coen-
zymes. This approach was applied in a study by Quinn
et al., where the healing potential of diabetic wounds was
evaluated in a diabetic mouse model [40]. Evaluation of
the NADH/FAD ratio may have an important diagnostic
value in the diagnosis of tissue oxygen metabolism disor-
der in DM [107]. Some studies have analyzed the differ-
ence in the AGE/NADH ratio between diabetics and
healthy controls [164]. They reported a significant
increase in this ratio among the former group.
2.6 | Optical coherence tomography
Optical coherence tomography (OCT) has found wide
application in the diagnosis of DM complications. This
technique is based on low-coherence interferometry and
provides a cross-sectional image of the tissue studied. It
can provide a two- or three-dimensional image of the tis-
sue by measuring the echo delay and the intensity of the
back reflected radiation (similar to the B-scan in ultraso-
nography). The method was developed in 1991 [165] and
immediately became widespread in various medical
applications, especially in ophthalmology.
OCT has been used in the diagnosis of DR and macular
edema since the first commercial OCT scanners were intro-
duced in 1995 [166]. Macular edema is a common cause of
vision loss in diabetes, which can occur at any stage of the
disease. The introduction of OCT in ophthalmology has
dramatically improved the diagnosis of DR. Changes in the
state of the retina and its blood supply can reflect a number
of pathophysiological reactions to hypertension, inflamma-
tion, hyperglycemia, hypoxia and endothelial dysfunction,
and thus can predict various microvascular complications
of diabetes. At the beginning of the 1990s, the possibilities
of diagnosing eye diseases using OCT were shown, and in
a 1998 study, [42] OCT was used to evaluate macular thick-
ening in patients with diabetes. Subsequent studies have
confirmed the reproducibility of retinal thickening mea-
surements using OCT [43].
In the studies conducted with time-domain OCT (TD-
OCT), it was shown that patients with diabetes generally
do not show differences in the retinal thickness com-
pared with a healthy control group [167]. Concurrently,
studies using spectral-domain OCT (SD-OCT) showed
differences in the thickness of some layers of cells
between diabetic patients without visible signs of DR and
a healthy control group [44, 168]; in particular, the differ-
ence was observed for the layer of photoreceptors [45]. In
addition, the dependence of this parameter on the dura-
tion of the disease [45] was demonstrated. A significant
advantage of SD-OCT is that this method facilitates the
analysis of a larger number of eye structures and the eval-
uation of the integrity of the outer layer of the retina.
SD-OCT was used to assess the choroidal thickness in
patients with diabetic macular edema and various stages
FIGURE 7 AGE-Reader (DiagnOptics) [161]
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of DR and a control group [46, 47], showing a decrease in
this parameter in patients with diabetes, which may be
one of the reasons for the development of eye disorders
in this disease. The studies have been conducted on eval-
uating the effectiveness of macular edema treatments,
demonstrating differences in the structure of the treated
and untreated eye recorded by SD-OCT [166].
Recent investigations with advances in SD-OCT rev-
ealed significant changes in the nuclei and dendrites of
retinal ganglion cells in patients with diabetes [48]. Sur-
prisingly, a thinning of these structures was found not
only among patients with advanced stages of DR, but also
among those not showing signs of complications. More
recent studies have linked changes in the structure of the
retinal nerve tissues with the development of diabetic
neuropathy, not retinopathy [49].
One of the promising directions in the diagnosis of
microcirculation in ophthalmology is the use of optical
coherence tomography angiography (OCTA). The
method produces numerous B-scans of the retina, all-
owing visualization of the vascular system by recording
changes in the intensity or phase of the OCT signal
that appear as a result of blood movement. OCTA has
been used to assess various retinal vascular changes
that occur during the development of DM with or with-
out DR [50–52], including microaneurysms, vascular
loops, nonperfusion, neovascularization and foveal
avascular zone erosion. Figure 8 presents the results of
retinal perfusion measurements with OCTA of a con-
trol group and diabetic subjects with different stages of
DR [53].
The OCT method is also widely used to assess wound
healing. Several experiments have been conducted with
laboratory animals [169, 170], as well as studies of burns
[171–173]. However, similar studies of diabetic wounds
were not identified.
Some studies were conducted on the estimation of the
concentration of various substances using OCT, including
the estimation of glucose and glycated hemoglobin in
solutions and optical phantoms. The change in the opti-
cal properties of blood after the addition of glucose has
been studied. The study of Galanzha and co-authors com-
pared OCT measurements of different concentrations of
glycated hemoglobin solutions in distilled water [56, 57].
In 2001, R. Esenaliev et al. demonstrated the ability of
OCT to measure the concentration of blood glucose in
phantoms and in animal models [54]. In their study, they
compared the noninvasively measured OCT signal and
glucometer data with a rapid glucose injection. They later
confirmed that the results of measurements of the OCT
curve slope correlate with measurements of blood sugar
using a glucometer in the first clinical study performed
on healthy volunteers [55].
2.7 | Confocal microscopy
The method of corneal confocal microscopy (CCM) is
widely used in assessing eye changes between the healthy
and diseased states [174, 175]. The technique allows the
study of the corneal architecture under high magnifica-
tion to evaluate the condition of the corneal nerves, for
the diagnosis of DM complications. The principle is based
on confocal optics, limiting the area of observation to a
single point. In the study of the population of patients
with diabetes using this technology, a correlation was
FIGURE 8 Series of color fundus
photos (top row), OCT angiograms
(middle row), and color-coded vascular
perfusion maps (lower row)
demonstrating changes in perfusion
density seen as diabetic retinopathy
progresses [53] (NPDR, nonproliferative
diabetic retinopathy; PDR, proliferative
diabetic retinopathy). Reproduced with
permission of Springer Nature
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found between a decrease in the nerve fiber density and
the severity of neuropathy [58]. In addition, it has been
shown that diabetic nerve fibers are more tortuous,
which is inversely correlated with the severity of diabetic
neuropathy [59]. The authors believe that the tortuosity
of the fibers can be associated with nerve regeneration
and improved glycemic control [59, 175], similar to the
previous animal studies [176]. Figure 9 presents CCM
images of patients with varying degrees of diabetic neu-
ropathy and a control group.
CCM was also used in recently diagnosed type 2 diabe-
tes to detect early signs of neuropathy [60], showing
greater sensitivity compared to the skin biopsy studies in
some cases. The studies were conducted on changes in
nervous corneal innervation during pancreas and kidney
transplantations in patients with type 1 DM [61, 62]. A
significant improvement in the density and length of the
corneal nerve fibers was shown compared with the pre-
operative state. The authors conclude that CCM appears
to represent a promising noninvasive and reiterative test
with high sensitivity for assessing the benefits of pancreas
transplantation and other therapies in clinical trials of
human diabetic neuropathy.
2.8 | Raman spectroscopy
The Raman spectroscopy is based on inelastic scattering
of monochromatic light by matter, which leads to energy
transfer and molecular vibrations. The technique pro-
vides a highly specific probe with unique chemical finger-
printing of molecules. The method has found wide
application in pharmacology, microbiology and human
biology. A considerable number of studies have been
done in oncology [178]. Traditional Raman spectroscopy
has been used in the diabetic studies to assess the concen-
tration of blood glucose in a sample [179]. Later, a nonin-
vasive assessment of blood glucose concentration using
Raman spectroscopy was carried out in an experiment on
a mouse model [180]. The ability of the method to detect
differences in the blood and serum of subjects with diabe-
tes and healthy subjects based on the spectra of glucose,
lipids, leucine and isoleucine amino acids was demon-
strated [181, 182]. Thus, it has been shown that Raman
spectroscopy can be a reliable method for diabetes screen-
ing in blood samples. It can also potentially be used to
evaluate the effectiveness in diabetes therapy [181, 183].
The method has also been used to evaluate protein
glycation in diabetes. For these purposes, numerous mod-
ifications of traditional Raman spectroscopy were used,
including surface-enhanced Raman spectroscopy (SERS).
In a study conducted by Kiran et al. [64], the possibility
of using surface-enhanced resonance Raman spectros-
copy (SERRS) to assess the accumulation of glycated
hemoglobin, one of the most used markers for long-term
glycemic control, was shown. In order to enhance the
recorded Raman signal, the authors applied a solution of
silver nanoparticles, after which they observed character-
istic SERRS peaks in the range of 770 to 830 nm in
HbA1c solution. It has also been proven that the peak at
a wavelength of 827 nm originates from the glycated
hemoglobin. The other study, conducted by Barman
et al., applied drop coating deposition for quantification
of HbA1c concentration in the whole blood [65].
The studies in the field of noninvasive assessment of
AGE accumulation using Raman spectroscopy are of par-
ticular interest. In a study conducted by Paolillo et al.,
Raman and fluorescence techniques were simultaneously
used [63]. In this study, the degradation of type I collagen
and increased glycation was shown in diabetics and
changes in the collagen hydration state was noted for dia-
betic and chronological aging groups, according to
Raman spectroscopy data. The combination of fluores-
cence and Raman spectroscopy techniques was proposed
for noninvasive diabetes diagnostics or diabetes risk pre-
diction. Earlier works have already indicated the possibil-
ity of Raman spectroscopy to differentiate skin subjected
to chronological changes or photoaging of young sun-
protected skin [184]. Skin Raman spectra are shown in
Figure 10.
FIGURE 9 Corneal confocal
microscopy images obtained for: A,
healthy volunteer (with typical beaded
appearance, density, mild tortuosity,
and adequate branching) and B, diabetic
subjects with severe diabetic neuropathy
showing single branch leaving main
nerve trunk at bottom of frame
[177]. Reproduced with permission of
Elsevier
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In another study, performed by Guevara et al., a por-
table implementation of a Raman spectroscopy was used
for the noninvasive screening of patients with type 2 dia-
betes [185]. Using machine learning and principal com-
ponents analysis, the authors were able to discriminate
between diabetic and control groups with an accuracy of
88.9% to 90.9%, depending on the measurement area.
Raman spectroscopy systems are usually equipped
with CW lasers at an excitation wavelength of 532 or
785 nm.
2.9 | Terahertz
Terahertz pulsed spectroscopy and imaging utilize elec-
tromagnetic radiation in the frequency band from 0.1 to
10 THz (with wavelength 0.3-3 mm). This frequency
range lies between the infrared and microwave ranges,
and allows noninvasive diagnostics of biological tissues.
THz imaging is highly sensitive to the water content of
tissues, and therefore, it has found application in the
fields of medicine related to the evaluation of biotissue
hydration. It has been tested in skin, lung, breast and
other types of cancer [186–188], as well as in assessing
burn severity [189, 190] and wound healing [191].
Although this method has not yet been widely used to
study the complications of diabetes, Hernandez-Cardoso et
al have shown in their article that it has potential applica-
bility in the diagnosis of diabetic foot syndrome [66]. Using
THz reflection imaging, the study revealed a significantly
reduced level of foot tissue hydration in patients with dia-
betes compared with healthy subjects and proposed this
technique as a potential screening method for the early
stages of diabetic foot syndrome. Figure 11 shows the THz
images of the feet of control subjects and patients with DM.
2.10 | Other techniques
Other optical technologies that, although not yet widely
adopted, have been used in the studies of DM and its
complications are also worth mentioning.
A large number of the in vitro studies on changes in
the optical properties of biological tissues under the influ-
ence of glycation were undertaken. Since our review is
devoted to noninvasive methods for assessing disorders
that occur during DM, we will not dwell on them in detail,
and just list some. Using refractometry, the changes in the
properties of red blood cells and hemoglobin solutions of
patients with DM were evaluated [192, 193]. It has been
proposed that these measurements be used to estimate the
concentration of glycated hemoglobin.
In the studies of skin biopsy samples using atomic
force microscopy (AFM), the changes in the mechanical
properties of collagen in patients were shown compared
with the control group [194]. The changes included a vio-
lation of the integrity of dermal collagen, disorganization
of collagen fibrils, and nanoscale fragmentation. Figure 12
shows the nanoscale images of the skin morphology of a
healthy subject and a patient with diabetes, as well as the
mechanical properties of the skin.
Measurements of the glucose concentration in water
solutions [195] and the accumulation of AGEs in pig skin
samples subjected to glycation in a ribose solution [196]
were conducted by optoacoustic spectroscopy. The
authors claim that although optoacoustic methods have
some drawbacks, such as the influence of the optical
properties of the skin and their changes on the result,
they have potential to overcome the limitations of purely
optical spectroscopic methods.
FIGURE 10 Raman spectra of skin [63]. Reproduced with
permission of John Wiley and Sons
FIGURE 11 Terahertz images of a typical member of the, A,
control and, B, diabetic groups. Volumetric fraction of water for
control and diabetic group members, C, averaged over the foot
sole, D, at the center of the greater toe, and, E, at the center of the
heel. Each point represents a subject [66]
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FIGURE 12 Collagen fibril nanoscale morphology and mechanical properties of diabetic skin: A, Nanoscale collagen fibrils imaged by
AFM. The white and red arrow heads indicate intact and fragmented/disorganized collagen fibrils, respectively. B, Three-dimensional
nanoscale collagen fibrils imaged by AFM. C, Collagen fibril roughness analyzed using nanoscope analysis software, *p < .05. D, Tensile
strength, E, traction forces, and F, deformation, *p < .05 [194]
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Photoacoustic (optoacoustic) tomography (PAT) is
widely used to analyze vascular disorders in PAD. Previous
studies have shown the potential of technology in vascular
imaging for a number of pathological changes, including
oncology [197, 198], systemic sclerosis [199], disorders of
cerebrovascular blood flow [200] and so on. Although the
technology has already found wide application in the stud-
ies of vascular complications of various etiologies, it is little
used in the studies of diabetes complications. At the
moment, only a few examples of in vivo studies are con-
ducted in the field of diabetes using PAT. In the work of
Yang et al. [201] it was shown that PAT has a potential in
the diagnosis of vascular function (on the example of
changes arising from arterial and venous occlusion).
Diffusion optical tomography (DOT) was used in the
studies of PAD [202, 203] and to assess the quality of dia-
betic ulcer healing [204]. The technique is based on sens-
ing tissue with light of several wavelengths in the red and
infrared ranges, followed by reconstructing two- and
three-dimensional maps of tissue oxygenation and blood
volume. The studies have shown that there are differences
in changes in hemoglobin concentration in a healthy con-
trol group, patients with PAD, and a diabetic PAD cohort
[203]. It is believed that DOT can significantly aid the
diagnosis and treatment of diabetic foot disorders, provid-
ing information on the distribution of blood flow in the
most compromised areas of the foot. The studies of dia-
betic ulcers in model animals using this technology
showed significantly increased light absorption and scat-
tering in the ulcer area in the diabetic group compared to
the control group. An increasing trend in the absorption
coefficient of diabetic ulcers during healing was shown,
while in the control group, absorption remained almost
constant throughout the healing process [204]. The
authors associate such changes in diabetic animals with
the process of the wound vascularization.
3 | CONCLUSIONS
Optical noninvasive diagnostic technologies are promis-
ing in the study of diabetes complications and have a
large potential to aid clinical assessment. By using bio-
photonics methods, it is possible to assess the state of the
microvasculature, monitor changes in tissue innervation
and diagnose the effectiveness of diabetes therapy. Vari-
ous spectroscopic and imaging techniques can evaluate
parameters such as blood supply to tissues, degree of oxy-
gen saturation, presence and concentration of various
chromophores, and assess changes in the structure and
functioning of different body systems.
In this review, we examined the use of various bio-
photonic methods. All of them can identify certain
disorders that occur with diabetes, and seem promising
in the field of early diagnosis and prevention of complica-
tions. However, most of these methods have not yet
become widespread in clinical practice. Some technolo-
gies, such as OCT, are currently widely applied in certain
areas of medicine, and further technical advances will
increase the scope of its application. Other technologies,
such as LDF, despite a significant scientific base, are not
widely used in the clinic due to some methodological
difficulties.
Recent advances in the optical noninvasive diagnosis
of diabetes complications suggest a wider adoption of
optical technology in clinical practice in the near future.
We assume that such technologies as hyperspectral, fluo-
rescence and speckle-contrast imaging are the closest to
widespread implementation in clinical practice and can
already be used in the work of the attending physician.
Also, the combination of several biophotonics technolo-
gies for multiparametric diagnostics has great potential,
but all the technologies described require further studies
with thorough testing in the clinic. Finally, due to strong
multiple scattering of light in biological tissues (especially
skin) [7] optical imaging techniques are required to apply
optical clearing agents to overcome a limitation associ-
ated with the narrow probing depth [205, 206].
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